


## CLAIMS

1. A compound of the following general formula (I):



(I)

wherein

$R_2$  designates hydrogen, Me, Et, CHO, CN, OH, OMe, COR<sub>9</sub>, COOR<sub>9</sub>, CONHR<sub>9</sub> or CSNHR<sub>9</sub>, whereby  $R_9$  denotes (C<sub>1</sub>-C<sub>4</sub>)alkyl;

$R_5$  designates hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, OH, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, OCF<sub>3</sub>, trifluoromethyl or halogen;

$R_6$  designates Me, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, OCF<sub>3</sub>, SMe or SEt;

$n$  is 1 or 2;

$R_3'$  and  $R_5'$  each independently designate OH, Me, Et, OMe, OCF<sub>3</sub>, trifluoromethyl or halogen;

$U$  designates N or CR<sub>2</sub>', whereby  $R_2'$  denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, trifluoromethyl or halogen;

$V$  designates N or CR<sub>4</sub>', whereby  $R_4'$  denotes hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, OH, trifluoromethyl or halogen;

$W$  designates N or CR<sub>6</sub>', whereby  $R_6'$  denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, trifluoromethyl or halogen;

and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein  $R_2$  desig-

nates Me, OH, CN, CHO, COR<sub>9</sub> or COOR<sub>9</sub>.

3. A compound according to claim 1, wherein R<sub>2</sub> designates Me, CN, CHO or COMe.

5

4. A compound according to one of claims 1 to 3, wherein R<sub>5</sub> designates hydrogen, Me, OMe or halogen.

10

5. A compound according to one of claims 1 to 4, wherein R<sub>6</sub> designates OMe or OEt.

6. A compound according to one of claims 1 to 3, wherein R<sub>5</sub> designates hydrogen or OMe, preferably hydrogen; and R<sub>6</sub> designates OMe.

15

7. A compound according to one of claims 1 to 6, wherein R<sub>3</sub>' and R<sub>5</sub>' each independently designate chloro, bromo, Me or OMe.

20

8. A compound according to claim 1 to 7, wherein R<sub>3</sub>' and R<sub>5</sub>' are identical; or R<sub>3</sub>' designates chloro or bromo, and R<sub>5</sub>' designates OMe.

25

9. A compound according to claim 7, wherein R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.

10. A compound according to one of claims 1 to 9, wherein U and W designate CH and V designates CR<sub>4</sub>'.

30

11. A compound according to claim 10, wherein R<sub>4</sub>' designates hydrogen, chloro, bromo, Me or OMe.

12. A compound according to claim 10, wherein R<sub>3</sub>' , R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>3</sub>' designates chloro and R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>4</sub>' designates hydrogen and R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.

5 13. A compound according to claim 1, which is 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-

10  
15  
20  
25  
30

cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-

dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, or a pharmaceutically acceptable salt thereof.

14. A compound according to anyone of claims 1 to 13, which is the (R)- or (S)-enantiomer.

5 15. A compound as defined in one of claims 1 to 14, for use as a medicament.

16. Use of a compound as defined in one of claims 1 to 14, for the preparation of a medicament for the prophylaxis or treatment of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is  
10 beneficial.

17. The use according to claim 16, wherein the disease is selected from cell proliferate diseases such as cancer, atherosclerosis, restenosis, inflammatory diseases such as  
15 psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

18. A method of treatment or prophylaxis of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, in a subject in  
20 need of such treatment or prophylaxis, comprising administering to said subject an amount of a compound (I) as defined in one of claims 1 to 14 in an amount which is effective in down-regulating or inhibiting the expression or function of the IGF-1 receptor.

25 19. The method of claim 18, wherein the disease is selected from cell proliferate diseases such as cancer, athero-

sclerosis, restenosis, inflammatory diseases such as psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

20. A pharmaceutical composition comprising a compound  
5 of formula (I), or a pharmaceutically acceptable salt thereof  
as defined in any one of claims 1 to 14, and a pharmaceuti-  
cally acceptable adjuvant, diluent or carrier.

21. Articles containing a compound of the formula (I)  
10 or a pharmaceutically acceptable salt thereof as defined in  
any one of claims 1 to 14, and a chemotherapeutic agent, as a  
combination for the simultaneous, separate or successive ad-  
ministration in the therapy of a disease in which down-regu-  
lation or inhibition of the expression or function of the  
15 IGF-1 receptor is beneficial.

22. Use of a compound of the formula (I) or a pharma-  
ceutically acceptable salt thereof as defined in any of  
claims 1 to 14, as a pharmacological tool in the development  
and standardization of in vitro and in vivo test systems for  
20 the evaluation of the effects of inhibitors of cell cycle ac-  
tivity in laboratory animals.